{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041385","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.260313+00:00","generated_at":"2026-06-11T17:26:05.475688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control","bullets":["Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.","Net loss Q2 2023 $7.6M ($0.54/share) vs $9.2M ($0.79/share) in Q2 2022.","TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% (5/29) for control; confirmed ORR 17.5% vs 10.3%.","47.5% of TPST-1120 arm patients on treatment vs 23.3% in control; 80% on study vs 50%.","Expect to discuss updated TPST-1120 data from formal review in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041385","json":"https://secwatch.observer/filing/0000950170-23-041385.json","markdown":"https://secwatch.observer/filing/0000950170-23-041385.md","text":"https://secwatch.observer/filing/0000950170-23-041385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/tpst-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:26:05.475688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0781e05bb0cb8cbe9bff39a4e5f74383168c8a2e","claim":"Tempest Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, EPS $0.54.","evidence_excerpt":"Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively, compared to $9.2 million and $0.79, respectively, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss and net loss per share for the quarter ended June 30, 2023 were $7.6 million and $0.54, respectively"},{"label":"EPS","value":"$0.54"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eca4061ffe3309f69f0b1650a6d334cf2a6b0927","claim":"Tempest Therapeutics, Inc. reported the six months ended June 30, 2023 results: net income Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, EPS $1.09.","evidence_excerpt":"Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively, compared to $17.7 million and $1.88, respectively, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017023041385/0000950170-23-041385-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"Net loss and net loss per share for the six months ended June 30, 2023 were $15.2 million and $1.09, respectively"},{"label":"EPS","value":"$1.09"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}